HIGHLIGHTS
- who: Qizheng Li from the University Belfast, United Kingdom have published the Article: Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report, in the Journal: (JOURNAL) of 26/Oct/2016
- how: The results showed that OS (primary endpoint) of the fruquintinib group and the placebo group was 9.30 months (95% confidence interval (CI) 8.18-10.45) and 6.57 months (95% CI 5.88-8.11) respectively the PFS (secondary endpoint) was 3.71 months (95% CI 3.654.63) and 1 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.